2023
AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers
Abu-Khalaf M, Alex Hodge K, Hatzis C, Baldelli E, El Gazzah E, Valdes F, Sikov W, Mita M, Denduluri N, Murphy R, Zelterman D, Liotta L, Dunetz B, Dunetz R, Petricoin E, Pierobon M. AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers. Npj Precision Oncology 2023, 7: 18. PMID: 36797347, PMCID: PMC9935518, DOI: 10.1038/s41698-023-00360-5.Peer-Reviewed Original ResearchEndocrine therapyProgressive diseaseCDK4/6 inhibitionImmune cellsTumor epitheliumOpen-label multicenter clinical trialMetastatic breast cancer patientsPI3K/AKT/mTOR activationFirst-line treatmentMetastatic breast cancerBreast cancer patientsAkt/mTOR activationMulticenter clinical trialAkt/mTORMBC patientsCancer patientsPredictive markerClinical trialsDisease progressionBreast cancerTreatment selectionTissue biopsiesPatientsNumber of FDAMTOR activation
2020
CDK 4/6 drug target activation mapping of HR+/HER2- metastatic breast cancer for treatment selection and response prediction.
Abu-Khalaf M, Hatzis C, Hodge K, Valdes F, Sikov W, Mita M, Denduluri N, Awerkamp K, Murphy R, Zelterman D, Dunetz B, Petricoin E, Pierobon M. CDK 4/6 drug target activation mapping of HR+/HER2- metastatic breast cancer for treatment selection and response prediction. Journal Of Clinical Oncology 2020, 38: e13029-e13029. DOI: 10.1200/jco.2020.38.15_suppl.e13029.Peer-Reviewed Original ResearchMetastatic breast cancerBreast cancerCyclin D1CDK 4/6 inhibitorsBaseline tumor tissueClass of drugsAdjuvant settingEndocrine therapyTherapy initiationFrontline therapyInhibitor therapyPFS intervalStudy treatmentPredictive markerDisease progressionClinical trialsOutcome dataTreatment selectionPathway biomarkersBiopsy materialAverage age 62Tumor tissuePatientsFinal analysisTop quartile
2016
Lower Rates of Influenza Infection Following Two Dose Series of High Dose Vaccination in Plasma Cell Disorders: Results of a Randomized, Double-Blind, Placebo-Assisted Clinical Trial
Branagan A, Duffy E, Parker T, Seropian S, Foster C, Zhang L, Verma R, Zelterman D, Gan G, Brandt D, Kortmansky J, Witt D, Ferencz T, Dhodapkar M. Lower Rates of Influenza Infection Following Two Dose Series of High Dose Vaccination in Plasma Cell Disorders: Results of a Randomized, Double-Blind, Placebo-Assisted Clinical Trial. Blood 2016, 128: 2139. DOI: 10.1182/blood.v128.22.2139.2139.Peer-Reviewed Original ResearchHigh-dose influenza vaccinePlasma cell disordersInfluenza vaccinationCell-mediated immunityInfluenza vaccineInfluenza infectionCell disordersClinical correlatesVaccination strategiesPCD patientsRandomized studySingle vaccineClinical trialsDose seriesFlu seasonInfection rateHigh-dose influenza vaccinationLaboratory-confirmed influenza infectionTwo-dose vaccination strategyHigh-dose vaccinationHigh-dose vaccineInfluenza vaccination strategiesPresent randomized studySerologic response rateSeasonal influenza vaccination
1983
Differences in biological activity among batches of lyophilized tice Bacillus Calmette-Guérin and their association with clinical course in Stage I lung cancer.
Bennett J, Gruft H, McKneally M, Zelterman D, Crispen R. Differences in biological activity among batches of lyophilized tice Bacillus Calmette-Guérin and their association with clinical course in Stage I lung cancer. Cancer Research 1983, 43: 4183-90. PMID: 6347367.Peer-Reviewed Original ResearchConceptsBacillus Calmette-GuérinLung Cancer Study GroupCancer Study GroupTumor cellsCalmette-GuérinStudy groupNorth American Lung Cancer Study GroupStage I lung cancer patientsStage I lung cancerI lung cancerAntitumor activityDisease-free intervalProlongation of survivalLung cancer patientsFuture clinical trialsAdjuvant therapyClinical courseCancer patientsLung cancerClinical trialsSolid tumor growthTumor growthTumor colonizationPreclinical testingLethal dose